Bringing a new therapy to market is one of the most complex and high-stakes undertakings in the pharmaceutical industry. Success is not only about regulatory approval or strong clinical data—it’s also about ensuring the product is launched into an environment that is prepared, receptive, and aligned with patient needs.
That’s where patient and stakeholder mapping, network analysis, and early initiatives play a pivotal role.
Understanding the Ecosystem
Every therapeutic area has a unique ecosystem of decision-makers and influencers. Regulatory agencies and payers may hold the keys to access, but advocacy groups, clinicians, and patient communities drive awareness, uptake, and long-term impact.
Without a clear picture of this ecosystem, companies risk misaligned strategies, missed opportunities, and slower adoption.
Patient & Stakeholder Mapping
Patient advocacy groups are increasingly central to shaping launch success. They amplify unmet needs, influence trial recruitment, and engage in policy discussions that affect reimbursement and access.
Stakeholder mapping goes beyond advocacy groups, capturing:
-
Clinicians & KOLs – trusted voices who guide prescribing.
-
Policy influencers – organizations and individuals who shape health priorities.
-
Payers & HTA bodies – whose decisions impact commercial viability.
-
Digital opinion leaders – whose reach can shape public perception.
Mapping provides clarity on who matters most and how to engage effectively.
Network Maps: Seeing the Connections
Traditional stakeholder lists are static. Network maps bring them to life, showing the relationships between advocacy groups, clinicians, policymakers, and industry bodies.
-
Who collaborates with whom?
-
Where are the central nodes of influence?
-
Which connections could open doors—or create barriers?
By visualizing these links, companies can prioritize engagement strategies that create momentum instead of fragmentation.
Key Initiatives for Opening Assets
For early-stage or “opening assets” in a portfolio, the launch journey begins well before commercial readiness. Strategic initiatives can build awareness, credibility, and alignment:
-
Early dialogue with patient groups to integrate perspectives into trial design.
-
Education programs that address gaps in disease awareness.
-
Policy roundtables that put unmet needs on the agenda.
-
Cross-stakeholder collaborations that foster trust and advocacy.
These initiatives establish a foundation of support that accelerates access and uptake once the product is approved.
Turning Insight Into Impact
At Elliogen, we help pharmaceutical and biotech companies prepare for launch by combining patient and stakeholder mapping, network visualisation, and tailored initiatives into a clear roadmap.
The result? Launches that don’t just check boxes but create meaningful, sustained impact for patients and healthcare systems.
If your company is preparing for launch and wants to strengthen patient and stakeholder engagement, we’d be happy to discuss how we can help, contact us at hello@elliogen.com
Leave a Reply